Parkinson's imaging agent re-enters phase III tests
This article was originally published in Clinica
Executive Summary
Boston Life Sciences is hoping to bolster its chances of securing US approval for its Altropane imaging agent for diagnosing Parkinsonian syndromes, by starting yet another round of phase III trials.